Orchard therapeutics plc (ORTX)
CashFlow / Quarterly
Mar'20Mar'19
Cash flows from operating activities:
Net loss attributable to ordinary shareholders

-50,569

-30,739

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

500

400

Non-cash share-based compensation

9,479

3,821

Amortization of Strimvelis loss provision

1,691

1,525

Other non-cash adjustments

-6,537

-3,224

Changes in operating assets and liabilities:
Trade receivables

-670

-2,177

Research and development tax credit receivable

3,385

5,242

Prepaid expenses, other current assets and other assets

2,500

-58

Operating leases, right-of-use assets

1,025

41

Accounts payable, accrued expenses and other current liabilities

-8,903

-16,089

Other long-term liabilities

-

-499

Operating lease liabilities

-1,047

645

Net cash used in operating activities

-49,902

-43,762

Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities

68,143

-

Payment of construction deposit

10,000

-

Purchases of property and equipment

1,329

529

Net cash provided by (used in) investing activities

56,814

-529

Cash flows from financing activities:
Proceeds from exercise of share options

1,438

5

Net cash provided by financing activities

1,438

5

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

-303

3,852

Net increase (decrease) in cash, cash equivalents and restricted cash

8,047

-40,434

Supplemental disclosure of non-cash investing and financing activities
Property and equipment included in accounts payable and accrued expenses

382

-

Lease assets obtained in exchange for new operating lease liabilities

3,752

-

Supplemental disclosure of cash flow information:
Cash paid for interest

485

-